EU Seeking Firms To Offer ‘Ever-Warm’ Production Capacity For Future Pandemics
The EU is drawing on lessons learned during the COVID-19 pandemic to set up a network of vaccine production capacities able to respond quickly to a surge in demand.
You may also be interested in...
Concerns by the drug industry over “complex and burdensome” regulatory requirements regarding security of supply could be addressed in the upcoming revision of the EU pharmaceutical legislation, suggests a report on the European Commission’s “structured dialog” process for tackling medicine supply chain vulnerabilities.
The European Commission has come in for criticism over the way it handled the procurement of COVID-19 vaccines in the initial stages of the pandemic, particularly the lack of provisions in contracts with manufacturers regarding possible supply disruptions.
The director-general of the European Commission’s recently-formed Health Emergency Response Authority addressed delegates at the off-patent association Medicines for Europe’s 2022 annual conference, noting that HERA was preparing a report for post-summer as it assessed its priorities.